NFE2L2 and cancer: Of the currently 487 LUSC samples in TCGA (Pan-cancer Atlas), 21% have PTEN mutations (around 100 patients); but only 10 samples exhibit PTEN and NFE2L2 mutations and only 8 show PTEN and KEAP1 co-existing mutations (Fig. S1D).